ate changes in categorical and continuous variables, respectively. RESULTS: Total of 102 patients who were followed up for 3 months are included in this analysis. Of which, 43.1% were male, mean age was 38.5 Ϯ 12.6 years old, and mean time since diagnosis was 8.9 Ϯ 8.4 years. The first reasons for initiating RLAI were insufficient response to previous medication (43.1%) and need for maintenance (24.5%). At 3-months, 98% of patients were still on RLAI treatment. Comparing the first 3-month treatment of RLAI to the 3-month period prior to the initiation of RLAI for the 102 patients, significant decreases were observed in the proportion of patients hospitalized (26.5% vs. 2.9%, p < 0.001) and the mean number of days in hospital (10.2 days vs. 1.3 days, p < 0.001). By 3-months, there were significant improvements in disease severity and patient functioning; the average CGI-S score significantly decreased from 3.74 at baseline to 3.33 at 3 months (p < 0.001) and the mean GAF score significantly increased from 51.5 at baseline to 56.0 at 3 months (p < 0.001). CONCLUSIONS: Based on the 3-month interim results, treatment with RLAI was associated with reductions in hospitalizations and improvements in disease severity and patient functioning in Russian patients with schizophrenia.
PMH4 EFFICACY AND SAFETY OF ORAL ATYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIA: A META-ANALYSIS INCLUDING PALIPERIDONE EXTENDED-RELEASE
Jones MP 1 , Nicholl D 2 , Trakas K 3 1 Macquarie University, North Ryde, Australia, 2 Johnson & Johnson, Raritan, NJ, USA, 3 Johnson & Johnson, Toronto, ON, Canada OBJECTIVES: Atypical antipsychotics are widely used in the pharmacologic management of schizophrenia. A meta-analysis of oral atypical antipsychotics was conducted to assess the relative effectiveness of a newly introduced agent, paliperidone extendedrelease (ER). METHODS: Randomized placebo-controlled studies of risperidone, olanzapine, quetiapine and aripiprazole were identified via a database search (MEDLINE, Embase, the Cochrane Library, PsycInfo and the Cumulative Index to Nursing & Allied Health Literature). Baseline demographic, efficacy and safety data were extracted and combined in the meta-analysis using the DerSimonian and Laird approach [1] . Random effects meta-regression 1 was used to assess potential confounding by patient mean age, gender ratio and duration of therapy on variability in efficacy and safety. RESULTS: Atypical antipsychotics as a group had lower odds of withdrawal for any reason than placebo treatment (OR 0.52, 95%CI 0.46, 0.58), with paliperidone ER having lower odds than the antipsychotic class as a whole (OR 0.43, 95%CI 0.34, 0.53). Odds of withdrawal due to adverse events were lower with paliperidone ER (OR 0.88, 95%CI 0.71, 1.15) than with risperidone (OR 2.09, 95%CI 0.80, 5.41) and with the atypical antipsychotics as a class (OR 1.02, 95%CI 0.83, 1.25). Paliperidone ER was associated with a lower odds of somnolence (OR 1.33, 95%CI 0.92, 1.94) than the atypical class (OR 1.70, 95%CI 1.39, 2.09) and a lower odds of weight gain (OR 1.75, 95%CI 1.29, 2.37) than all of the atypical antipsychotics, including risperidone (OR 3.08, 95%CI 1.53, 6.20). The predominant factor in the observed variability in efficacy was the specific antipsychotic, rather than patient-related factors or duration of therapy. CONCLUSIONS: Within the spectrum of efficacy and safety of the class, Paliperidone ER demonstrates a unique efficacy and tolerability profile. Owing to the heterogeneity within the class, information on individual benefit/risk profiles of atypical antipsychotics is necessary for selecting a specific treatment for each patient.
[1] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
PMH5

COMPARISON OF RISK OF UPPER GASTROINTESTINAL HEMORRHAGE AMONG SSRI-USERS WITHIN U.S. MANAGED CARE POPULATION
Kreilick C 1 , Seal B 2 , Tangirala M 3 1 PRO Unlimited, Bridgewater, NJ, USA, 2 Sanofi-Aventis, Bridgewater, NJ, USA, 3 Smith Hanley Consulting Group LLC, Lake Mary, FL, USA OBJECTIVES: Serotonin is critical for maintaining platelet haemostatic function such as aggregation. SSRI-induced upper gastrointestinal hemorrhage (UGIH) may occur through SSRIinduced inhibition of serotonin reuptake by platelets, leading to depletion of serotonin after several weeks of antidepressant (i.e. SSRI) treatment. The risk of SSRI-induced-UGIH has not been documented in a U.S. managed care population. The purpose of this study was to compare the incremental likelihood of UGIH events with use of SSRIs and in combination with NSAIDs in a managed care population. METHODS: A retrospective study was designed using data from a large managed care claims database. Subjects were identified anytime between October 1, 2005 to September 30, 2006 (index-period) and classified into SSRIusers, NSAID-users or SSRI-NSAID concomitant users. Each subject was matched to a control (non-SSRI/NSAID-user) based on their index date. All subjects were treatment naïve 12 months prior to their pre-index period and followed for 12 months post index date to determine the risk of any UGIH event based on ICD-9-CM code. RESULTS: A total of 87, 054, 275,476, 27,696, and 386,248 subjects were identified as SSRI-users, NSAIDusers, concomitant-users and controls at index-period. The control group was significantly (p < 0.001) younger than the drug cohorts (31vs. 42years), lower (p < 0.001) proportions of females (47% vs. 57%), and lower (p < 0.001) burden of comorbid illness as measured by Charlson Comorbidity Index (0.15 vs. 0.50). Compared to the controls, concomitant-users had 1.0% (OR = 3.32; 95%CI = 2.90-3.79), SSRI-users had 0.8% (RR = 2.59; 95%CI = 2.36-2.86), and NSAID-users had 0.5% (RR = 1.83; 95%CI = 1.69-1.97) cases with a diagnoses of UGIH. CONCLUSIONS: Current SSRIs that are recommended as first line therapy for depression is associated with a risk of UGIH within first 12-months either alone or in combination with NSAIDs. Future research needs to estimate the economic burden of such bleeding events to managed care.
PMH6 A SYSTEMATIC REVIEW ON THE EPIDEMIOLOGY AND SOCIOECONOMIC BURDEN OF BIPOLAR DISORDER IN EUROPE
Fajutrao L 1 , Locklear JC 2 , Priaulx J 3 , Heyes A 4 1 AstraZeneca R&D, Sodertalje, Sweden, 2 3AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 3 Mapi Values, Macclesfield, UK, 4 Mapi Values Ltd, Cheshire, UK OBJECTIVES: To determine the epidemiological, clinical, and economic burden of bipolar disorder (BD) in Europe. METHODS: A systematic review of publications from the last 10 years relating to the burden of bipolar disorder was conducted, including studies on epidemiology, patient-related issues, and costs. RESULTS: Data from the UK, Germany, and Italy indicated a prevalence of bipolar disorder of~1%, and a misdiagnosis rate of 70% from Spain. In one study, up to 75% of patients had at least one DSM-IV comorbidity, commonly anxiety disorders and substance/alcohol abuse. Attempted suicide rates varied between 21-54%, with 18% mortality in the UK. The chronicity of bipolar disorder exerted a profound and debilitating effect on the patient. Only 30% of German patients were employed full time at a level matching their qualifications. In Italy, 63-67% of patients were unemployed and in Germany, 72% received disability payments. In the UK, the annual costs of unemployment and suicide were £1510 million and £179 million, respectively. The estimated UK national cost of bipolar disorder was €4.59 billion, with hospitalization during acute episodes representing the largest component. CONCLUSIONS: Bipolar disorder is a major and underestimated health problem in Europe. A number of issues impact on the burden of the disease, such as comorbidities, suicide, early death, unemployment or underemployment. Direct costs of bipolar disorder are mainly associated with hospitalization during acute episodes. Indirect costs are a major contributor to the disease burden but are not always recognized in research studies. Supported by funding from AstraZeneca Pharmaceuticals LP.
PMH7
PREVALENCE OF POTENTIAL MEDICATION INTERACTIONS WITH ANTIPSYCHOTICS VIA CYTOCHROME P450 IN PATIENTS WITH SCHIZOPHRENIA IN GERMANY
Mehnert A 1 , Hargarter L 1 , Diels J 2 1 Janssen-Cilag GmbH, Neuss, NRW, Germany, 2 Johnson & Johnson Pharmaceutical Services, Beerse, Belgium OBJECTIVES: While pharmacological hepatic interaction mechanisms for antipsychotics are largely known, there is little research so far on the prevalence of potential interactions with other substances. The objective of the present study is to estimate the annual prevalence of potential pharmacokinetic drug-drug interactions (DDIs) between antipsychotic and non-antipsychotic therapies in patients with schizophrenia. METHODS: A retrospective analysis of drug prescriptions for patients treated for schizophrenia (ICD-10 codes F20-F29) was performed using the German IMS Disease Analyzer data for psychiatrists for 2007. These data originate from electronic medical records from a representative panel of German psychiatrists, and include drug prescriptions and medical diagnoses. Potential antipsychotic drug-drug interactions based on cytochrome P450 metabolism (1A2, 2D6, 3A4, and 3A pathways) for antipsychotics and corresponding interacting drugs (pathway inducers and inhibitors) were identified based on literature and drug information resources. A potential DDI was identified when combinations known to interact had 20 or more days of overlap, determined by prescription dates, dosing information and pack size. Incidence of overlap was calculated by antipsychotic, metabolic pathway and interaction mechanism. RESULTS: A total of 5449 patients received an atypical antipsychotic. The most frequent interaction mechanisms were inhibition of CYP2D6 and of CYP3A4: between 38% and 45% of the patients treated with atypicals had a 20 day-overlap with inhibitors of CYP2D6, and 17% to 26% with CYP3A4-Inhibitors. Potential interactions were most commonly associated with antidepressants. CONCLUSIONS: The risk of potential DDI in schizophrenia patients treated with antipsychotics in Germany is common, mainly due to concomitant prescription of antipsychotics and antidepressants. The reported estimates are based on real world data for psychiatrists in Germany, and are conservative, since drugs prescribed by other physicians or bought over the counter could not be taken into account.
PMH8 TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE QUETIAPINE COMPARED TO QUETIAPINE IMMEDIATE RELEASE IN THE TREATMENT OF ACUTE BIPOLAR DISORDER: AN ADJUSTED INDIRECT COMPARISON
Edwards SJ, Korim F AstraZeneca UK Ltd, Luton, UK OBJECTIVES: In 2002, the National Institute for Health and Clinical Excellence (NICE) highlighted extrapyramidal symp-toms (EPS), sexual dysfunction, sedation, and weight gain, as the outcomes considered by patients taking atypical antipsychotics to be the most troublesome. This research was designed to compare the tolerability of the new extended release quetiapine to the existing quetiapine immediate release formulation on these outcomes in addition to orthostatic hypotension, which could be a significant cause of morbidity. METHODS: Systematic review of CENTRAL, BIOSIS, EMBASE and MEDLINE for randomised controlled trials (RCTs) in patients with acute bipolar disorder treated with quetiapine was conducted in May 2008. Metaanalyses of quetiapine vs placebo used a random effects model. The results from the individual meta-analyses formed the basis of an adjusted indirect comparison of the two quetiapine formulations using placebo as a common comparator. Summary effect estimate for each outcome was calculated as relative risk (RR) with 95% confidence interval (95% CI) where RR < 1 favoured extended release and RR > 1 favoured immediate release. RESULTS: Of the 331 papers initially identified in the literature search, 5 RCTs compared quetiapine with placebo with a common daily dose of 300mg (4 RCTs immediate release and 1 RCT extended release). Adjusted indirect comparison identified no significant differences between the two formulations of quetiapine in the outcomes assessed. Individual results were as follows: EPS RR0.34 (95% CI: 0.04 to 12.07); orthostatic hypotension RR1.81 (95% CI: 0.19 to 57.84); prolactin RR1.92 (95%CI: 0.11 to 123.24); sedation RR1.09 (95%CI: 0.51 to 6.29); weight gain RR0.26 (95% CI: 0.05 to 6.86). CONCLU-SIONS: This adjusted indirect comparison of five placebocontrolled clinical trials suggests that the tolerability profile of extended release quetiapine is consistent with that of the immediate release formulation. Further research will need to be conducted to determine if these results are replicated in real-life clinical practice.
PMH9
TOLERABILITY OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS
Edwards SJ 1 , Smith CJ 2 1 AstraZeneca UK Ltd, Luton, UK, 2 Guy's Hospital and Maudsley Hospital, London, UK OBJECTIVES: To compare the tolerability profiles of atypical antipsychotics assessed in randomised controlled trials (RCTs). METHODS: Systematic review of BIOSIS, CENTRAL, EMBASE, MEDLINE, PsycINFO for RCTs comparing two or more atypical antipsychotics (aripiprazole-ARI, olanzapine-OLZ, quetiapine-QTP, risperidone-RSD, ziprasidone-ZPD). Searching was restricted to English-language publications and was completed in December 2007. Data were extracted on the following outcomes: anxiety or depression, bodily anxiety or restlessness, dizziness or nausea, extrapyramidal symptoms (EPS), sexual dysfunction, stiffness or tremor, tiredness or weakness, weight gain. Data were recalculated if not presented in an intention-to-treat format. Mixed treatment comparisons were conducted by Bayesian Markov Chain Monte Carlo simulation using uninformed priors. Summary effect estimates (Odds Ratios [OR], 95% credible intervals [95%CrI]) were calculated compared to RSD. RESULTS: Of the 2963 papers identified in the literature search, 50 were found to provide data on 48 RCTs comparing two or more atypical antipsychotics. The results presented a wide spectrum of tolerability among the atypical antipsychotics with no single treatment being identified as consistently better tolerated than all other. The outcomes that could be considered statistically significant at the 5% level were: decrease in Abstracts A581
